FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2583134829> ?p ?o ?g. }

• W2583134829 endingPage "15886" @default.
• W2583134829 startingPage "15878" @default.
• W2583134829 abstract "// Yang An 1, 2 , Haojie Wang 1, 2 , Jingyao Jie 1, 2 , Yitai Tang 3 , Weijuan Zhang 1, 2 , Shaoping Ji 1, 2, 4 , Xiangqian Guo 1, 2, 5, 6 1 Department of Biochemistry and Molecular Biology, Medical School, Henan University, Kaifeng 475004, China 2 Cell Signal Transduction Laboratory, Henan University, Kaifeng 475004, China 3 Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA 4 Department of Oncology, The First Affiliated Hospital of Henan University, Kaifeng, 475001, China 5 Department of Preventive Medicine, Medical School, Henan University, Kaifeng 475004, China 6 Department of Burn and Plastic Surgery, The Affiliated Nanshi Hospital of Henan University, Nanyang, 473003, China Correspondence to: Xiangqian Guo, email: xqguo@henu.edu.cn Shaoping Ji, email: shaopingji@163.com Keywords: uterine carcinosarcoma, molecular subtype, molecular signature, gene expression pattern, subtype-specific treatment Received: August 11, 2016      Accepted: January 06, 2017      Published: February 02, 2017 ABSTRACT Uterine carcinosarcoma (UCS) is a rare but lethal neoplasm with high metastasis and recurrence rate, and to date, no molecular classification of UCS has been defined to achieve targeted therapies. In this study, we identified two distinct molecular subtypes of UCS with distinct gene expression patterns and clinicopathologic characteristics. Subtype I UCS recapitulates low-grade UCS, in contrast subtype II UCS represents high-grade UCS with higher tumor invasion rate and tumor weight. Interestingly, subtype I UCS is characterized by cell adhesion and apoptosis pathways, whereas genes over-expressed in subtype II UCS are more involved in myogenesis/muscle development. We also proposed certain potential subtype specific therapeutic targets, such as SYK (spleen tyrosine kinase) for subtype I and cell-cycle proteins for subtype II. Our findings provide a better recognition of UCS molecular subtypes and subtype specific oncogenesis mechanisms, and can help develop more specific targeted treatment options for these tumors." @default.
• W2583134829 created "2017-02-10" @default.
• W2583134829 creator A5014477100 @default.
• W2583134829 creator A5015893405 @default.
• W2583134829 creator A5035731146 @default.
• W2583134829 creator A5061623278 @default.
• W2583134829 creator A5066504632 @default.
• W2583134829 creator A5089482025 @default.
• W2583134829 creator A5089731650 @default.
• W2583134829 date "2017-02-02" @default.
• W2583134829 modified "2023-10-06" @default.
• W2583134829 title "Identification of distinct molecular subtypes of uterine carcinosarcoma" @default.
• W2583134829 cites W133424498 @default.
• W2583134829 cites W1834145357 @default.
• W2583134829 cites W1901267188 @default.
• W2583134829 cites W1909261609 @default.
• W2583134829 cites W1963585692 @default.
• W2583134829 cites W1964840824 @default.
• W2583134829 cites W1967013964 @default.
• W2583134829 cites W1971301589 @default.
• W2583134829 cites W1974045043 @default.
• W2583134829 cites W1976402300 @default.
• W2583134829 cites W1979316630 @default.
• W2583134829 cites W1979491540 @default.
• W2583134829 cites W1987085807 @default.
• W2583134829 cites W1987971958 @default.
• W2583134829 cites W2000826244 @default.
• W2583134829 cites W2025675698 @default.
• W2583134829 cites W2027895157 @default.
• W2583134829 cites W2033775272 @default.
• W2583134829 cites W2037950256 @default.
• W2583134829 cites W2057033844 @default.
• W2583134829 cites W2061623831 @default.
• W2583134829 cites W2066878205 @default.
• W2583134829 cites W2067964015 @default.
• W2583134829 cites W2072176789 @default.
• W2583134829 cites W2072825436 @default.
• W2583134829 cites W2096979580 @default.
• W2583134829 cites W2113962581 @default.
• W2583134829 cites W2115462905 @default.
• W2583134829 cites W2117272130 @default.
• W2583134829 cites W2123696077 @default.
• W2583134829 cites W2129334913 @default.
• W2583134829 cites W2131905298 @default.
• W2583134829 cites W2131994307 @default.
• W2583134829 cites W2133431367 @default.
• W2583134829 cites W2135031820 @default.
• W2583134829 cites W2140116346 @default.
• W2583134829 cites W2154941270 @default.
• W2583134829 cites W2161289668 @default.
• W2583134829 cites W2163428244 @default.
• W2583134829 cites W2174586293 @default.
• W2583134829 cites W2263206910 @default.
• W2583134829 cites W2273649406 @default.
• W2583134829 cites W2286494756 @default.
• W2583134829 cites W2288305034 @default.
• W2583134829 cites W2316977373 @default.
• W2583134829 cites W2402797587 @default.
• W2583134829 cites W2422609099 @default.
• W2583134829 cites W4244607910 @default.
• W2583134829 cites W4254646606 @default.
• W2583134829 doi "https://doi.org/10.18632/oncotarget.15032" @default.
• W2583134829 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5362530" @default.
• W2583134829 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28178664" @default.
• W2583134829 hasPublicationYear "2017" @default.
• W2583134829 type Work @default.
• W2583134829 sameAs 2583134829 @default.
• W2583134829 citedByCount "9" @default.
• W2583134829 countsByYear W25831348292017 @default.
• W2583134829 countsByYear W25831348292018 @default.
• W2583134829 countsByYear W25831348292019 @default.
• W2583134829 countsByYear W25831348292020 @default.
• W2583134829 countsByYear W25831348292021 @default.
• W2583134829 crossrefType "journal-article" @default.
• W2583134829 hasAuthorship W2583134829A5014477100 @default.
• W2583134829 hasAuthorship W2583134829A5015893405 @default.
• W2583134829 hasAuthorship W2583134829A5035731146 @default.
• W2583134829 hasAuthorship W2583134829A5061623278 @default.
• W2583134829 hasAuthorship W2583134829A5066504632 @default.
• W2583134829 hasAuthorship W2583134829A5089482025 @default.
• W2583134829 hasAuthorship W2583134829A5089731650 @default.
• W2583134829 hasBestOaLocation W25831348291 @default.
• W2583134829 hasConcept C121608353 @default.
• W2583134829 hasConcept C126322002 @default.
• W2583134829 hasConcept C143998085 @default.
• W2583134829 hasConcept C204232928 @default.
• W2583134829 hasConcept C2777546739 @default.
• W2583134829 hasConcept C2778938455 @default.
• W2583134829 hasConcept C2779013556 @default.
• W2583134829 hasConcept C29537977 @default.
• W2583134829 hasConcept C502942594 @default.
• W2583134829 hasConcept C67082663 @default.
• W2583134829 hasConcept C71924100 @default.
• W2583134829 hasConceptScore W2583134829C121608353 @default.
• W2583134829 hasConceptScore W2583134829C126322002 @default.
• W2583134829 hasConceptScore W2583134829C143998085 @default.
• W2583134829 hasConceptScore W2583134829C204232928 @default.
• W2583134829 hasConceptScore W2583134829C2777546739 @default.

• next